Abstract
Crenolanib is a type I kinase inhibitor with activity against FLT3-ITD and secondary FLT3 mutants.
©2013 American Association for Cancer Research.
2013
You do not currently have access to this content.
Skip Nav Destination
Article navigation
1 November 2013
Research Watch|
November 06 2013
Crenolanib Is Effective Against Secondary FLT3 Mutations in AML Available to Purchase
Cancer Discov (2013) 3 (11): 1215.
RSS Feeds